Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Uchida, Kikuya Kato, Yoji Kukita, T. Kumagai, K. Nishino, H. Daga, Izumi Nagatomo, Takako Inoue, M. Kimura, Shigeyuki Oba, Yuri Ito, K. Takeda, F. Imamura (2015)
Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.Clinical chemistry, 61 9
L. Gorgannezhad, Muhammad Umer, Md Islam, N. Nguyen, M. Shiddiky (2018)
Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies.Lab on a chip, 18 8
A. Esposito, C. Criscitiello, D. Trapani, G. Curigliano (2017)
The Emerging Role of “Liquid Biopsies,” Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance MutationsCurrent Oncology Reports, 19
L. Bertero, G. Siravegna, R. Rudà, R. Soffietti, A. Bardelli, P. Cassoni (2019)
Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumoursNeuropathology and Applied Neurobiology, 45
Maha Elazezy, S. Joosse (2018)
Techniques of using circulating tumor DNA as a liquid biopsy component in cancer managementComputational and Structural Biotechnology Journal, 16
B. O’Leary, S. Hrebien, J. Morden, M. Beaney, C. Fribbens, Xin Huang, Yuan Liu, C. Bartlett, M. Koehler, M. Cristofanilli, I. Garcia-Murillas, J. Bliss, N. Turner (2018)
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancerNature Communications, 9
K. Payne, S. Gavan, S. Wright, A. Thompson (2018)
Cost-effectiveness analyses of genetic and genomic diagnostic testsNature Reviews Genetics, 19
I. Dagogo-Jack, A. Shaw (2018)
Tumour heterogeneity and resistance to cancer therapiesNature Reviews Clinical Oncology, 15
Ziqiang Lin, James Neiswender, B. Fang, Xuelei Ma, Jing Zhang, Xiuying Hu (2017)
Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysisOncotarget, 8
Kelly Plueschke, P. McGettigan, A. Pacurariu, X. Kurz, A. Cave (2018)
EU-funded initiatives for real world evidence: descriptive analysis of their characteristics and relevance for regulatory decision-makingBMJ Open, 8
M. Freidin, D. Freydina, M. Leung, A. Fernandez, A. Nicholson, E. Lim (2015)
Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies.Clinical chemistry, 61 10
J. Tabernero, H. Lenz, S. Siena, A. Sobrero, A. Falcone, M. Ychou, Y. Humblet, O. Bouché, L. Mineur, C. Barone, A. Adenis, T. Yoshino, R. Goldberg, D. Sargent, A. Wagner, D. Laurent, M. Teufel, M. Jeffers, A. Grothey, E. Cutsem (2015)
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.The Lancet. Oncology, 16 8
S. Ou, M. Nagasaka, V. Zhu (2018)
Liquid Biopsy to Identify Actionable Genomic Alterations.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 38
(2017)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
M. Arnedos, C. Vicier, S. Loi, C. Lefebvre, S. Michiels, H. Bonnefoi, F. André (2015)
Precision medicine for metastatic breast cancer—limitations and solutionsNature Reviews Clinical Oncology, 12
H. Schwarzenbach, J. Stoehlmacher, K. Pantel, E. Goekkurt (2008)
Detection and Monitoring of Cell‐Free DNA in Blood of Patients with Colorectal CancerAnnals of the New York Academy of Sciences, 1137
A. Hirakawa, J. Asano, Hiroyuki Sato, S. Teramukai (2018)
Master protocol trials in oncology: Review and new trial designsContemporary Clinical Trials Communications, 12
T. Glenn (2011)
Field guide to next‐generation DNA sequencersMolecular Ecology Resources, 11
Veronika Vymetálková, K. Cervena, Linda Bartu, P. Vodicka (2018)
Circulating Cell-Free DNA and Colorectal Cancer: A Systematic ReviewInternational Journal of Molecular Sciences, 19
C. Bettegowda, M. Sausen, R. Leary, Isaac Kinde, N. Agrawal, Bjarne Bartlett, Hao Wang, Brandon Luber, K. Kinzler, B. Vogelstein, N. Papadopoulos, L. Diaz (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesScience Translational Medicine, 6
Yang Wang, Tae Kim, S. Fouladdel, Zhuo-jun Zhang, Payal Soni, A. Qin, Lili Zhao, E. Azizi, T. Lawrence, N. Ramnath, K. Cuneo, S. Nagrath (2019)
PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung CancerScientific Reports, 9
(2019)
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome ConsortiumAnn Oncol, 30
(Marrugo-Ramírez J, Mir M, Samitier J. Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. Int J Mol Sci. 2018;19(10). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213360/. Accessed 30 Sep 2020.)
Marrugo-Ramírez J, Mir M, Samitier J. Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. Int J Mol Sci. 2018;19(10). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213360/. Accessed 30 Sep 2020.Marrugo-Ramírez J, Mir M, Samitier J. Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. Int J Mol Sci. 2018;19(10). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213360/. Accessed 30 Sep 2020., Marrugo-Ramírez J, Mir M, Samitier J. Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. Int J Mol Sci. 2018;19(10). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213360/. Accessed 30 Sep 2020.
K. Payne, Rachel Spruce, A. Beggs, N. Sharma, A. Kong, T. Martin, S. Parmar, P. Praveen, P. Nankivell, H. Mehanna (2018)
Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinomaHead & Neck, 40
Ruifeng Zhang, F. Shao, Xiaohong Wu, K. Ying (2010)
Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis.Lung cancer, 69 2
Jong Lee, J. Hur, I. Kim, Hee-Joung Kim, Chang-Min Choi, Jae Lee, W. Kim, K. Lee (2018)
Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNABMC Cancer, 18
Jose Marrugo-Ramírez, M. Mir, J. Samitier (2018)
Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue BiopsyInternational Journal of Molecular Sciences, 19
E. Wee, Yuling Wang, S. Tsao, M. Trau (2016)
Simple, Sensitive and Accurate Multiplex Detection of Clinically Important Melanoma DNA Mutations in Circulating Tumour DNA with SERS NanotagsTheranostics, 6
S. Jaiswal, P. Fontanillas, J. Flannick, A. Manning, Peter Grauman, B. Mar, R. Lindsley, C. Mermel, N. Burtt, A. Chavez, J. Higgins, V. Moltchanov, F. Kuo, M. Kluk, B. Henderson, L. Kinnunen, H. Koistinen, C. Ladenvall, G. Getz, A. Correa, B. Banahan, S. Gabriel, S. Kathiresan, H. Stringham, M. McCarthy, M. Boehnke, J. Tuomilehto, C. Haiman, L. Groop, G. Atzmon, James Wilson, D. Neuberg, D. Altshuler, B. Ebert (2014)
Age-related clonal hematopoiesis associated with adverse outcomes.The New England journal of medicine, 371 26
Surbhi Jain, Selena Lin, Wei Song, Ying-Hsiu Su (2019)
Urine-Based Liquid Biopsy for Nonurological Cancers.Genetic testing and molecular biomarkers, 23 4
Savazzi Gm (1981)
Nerve conduction times in uremia.International Journal of Artificial Organs, 4
(Nandi K, Verma R, Dawar R, Goswami B. Cell free DNA: revolution in molecular diagnostics—the journey so far. Horm Mol Biol Clin Investig. 2020;41(1):/j/hmbci.2020.41.issue-1/hmbci-2019-0012/hmbci-2019-0012.xml.)
Nandi K, Verma R, Dawar R, Goswami B. Cell free DNA: revolution in molecular diagnostics—the journey so far. Horm Mol Biol Clin Investig. 2020;41(1):/j/hmbci.2020.41.issue-1/hmbci-2019-0012/hmbci-2019-0012.xml.Nandi K, Verma R, Dawar R, Goswami B. Cell free DNA: revolution in molecular diagnostics—the journey so far. Horm Mol Biol Clin Investig. 2020;41(1):/j/hmbci.2020.41.issue-1/hmbci-2019-0012/hmbci-2019-0012.xml., Nandi K, Verma R, Dawar R, Goswami B. Cell free DNA: revolution in molecular diagnostics—the journey so far. Horm Mol Biol Clin Investig. 2020;41(1):/j/hmbci.2020.41.issue-1/hmbci-2019-0012/hmbci-2019-0012.xml.
Jun-Min Liu, Xuehua Chen, Juxian Wang, S. Zhou, Changli Wang, M. Ye, Xiuwen Wang, Yunhu Song, Y. Wang, Lin Zhang, R. Wu, H. Yang, Shida Zhu, Mengni Zhou, Xiaochun Zhang, H. Zhu, Z. Qian (2019)
Biological background of the genomic variations of cf-DNA in healthy individualsAnnals of Oncology, 30
Chunyan Yue, Yubo Jiang, Ping Li, Yuehua Wang, J. Xue, Nannan Li, Da Li, Ruina Wang, Yongjun Dang, Zhiyuan Hu, Yanlian Yang, Jianming Xu (2018)
Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapyOncoimmunology, 7
G. Genovese, A. Kähler, R. Handsaker, J. Lindberg, S. Rose, S. Bakhoum, K. Chambert, E. Mick, B. Neale, M. Fromer, S. Purcell, Oscar Svantesson, M. Landén, M. Höglund, S. Lehmann, S. Gabriel, J. Moran, E. Lander, P. Sullivan, P. Sklar, H. Grönberg, C. Hultman, S. Mccarroll (2014)
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.The New England journal of medicine, 371 26
K. Phillips, J. Sakowski, J. Trosman, M. Douglas, S. Liang, P. Neumann (2013)
The economic value of personalized medicine tests: what we know and what we need to knowGenetics in Medicine, 16
Kjersti Tjensvoll, Morten Lapin, Tove Buhl, Satu Oltedal, Katrine Berry, B. Gilje, J. Søreide, M. Javle, Oddmund Nordgård, R. Smaaland (2016)
Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancerMolecular Oncology, 10
D. Haber, V. Velculescu (2014)
Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.Cancer discovery, 4 6
Joan Seoane, L. Mattos-Arruda, E. Rhun, Alberto Bardelli, Michael Weller (2019)
Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastasesAnnals of Oncology, 30
E. Green, J. Watson, F. Collins (2015)
Human Genome Project: Twenty-five years of big biologyNature, 526
Ivana Hench, J. Hench, M. Tolnay (2018)
Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal CancerFrontiers in Medicine, 5
IS Batth (2017)
10.1093/annonc/mdw619Ann Oncol, 28
I. Bhan, Kelly Mosesso, L. Goyal, Julia Philipp, M. Kalinich, J. Franses, Melissa Choz, R. Oklu, M. Toner, S. Maheswaran, D. Haber, A. Zhu, R. Chung, M. Aryee, D. Ting (2018)
Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease.Gastroenterology, 155 6
M. Ehrich, J. Tynan, Amin Mazloom, E. Almasri, Ron McCullough, T. Boomer, D. Grosu, Jason Chibuk (2017)
Genome-wide cfDNA screening: clinical laboratory experience with the first 10,000 casesGenetics in Medicine, 19
C. Abbosh, N. Birkbak, G. Wilson, M. Jamal-Hanjani, T. Constantin, R. Salari, J. Quesne, D. Moore, S. Veeriah, R. Rosenthal, T. Marafioti, E. Kırkızlar, T. Watkins, N. Mcgranahan, S. Ward, L. Martinson, Joan Riley, F. Fraioli, M. Bakir, E. Grönroos, F. Zambrana, R. Endozo, W. Bi, F. Fennessy, Nicole Sponer, Diana Johnson, J. Laycock, S. Shafi, J. Czyzewska-Khan, A. Rowan, T. Chambers, Nik Matthews, S. Turajlic, C. Hiley, S. Lee, M. Forster, T. Ahmad, M. Falzon, E. Borg, D. Lawrence, M. Hayward, S. Kolvekar, N. Panagiotopoulos, S. Janes, R. Thakrar, Asia Ahmed, F. Blackhall, Y. Summers, D. Hafez, A. Naik, Apratim Ganguly, S. Kareht, R. Shah, L. Joseph, A. Quinn, P. Crosbie, B. Naidu, G. Middleton, G. Langman, S. Trotter, M. Nicolson, H. Remmen, K. Kerr, M. Chetty, L. Gomersall, D. Fennell, A. Nakas, S. Rathinam, G. Anand, S. Khan, P. Russell, V. Ezhil, Babikir Ismail, Melanie Irvin-sellers, V. Prakash, J. Lester, M. Kornaszewska, R. Attanoos, Haydn Adams, H. Davies, D. Oukrif, A. Akarca, J. Hartley, H. Lowe, S. Lock, N. Iles, Harriet Bell, Y. Ngai, G. Elgar, Z. Szallasi, R. Schwarz, Javier Herrero, A. Stewart, S. Quezada, K. Peggs, P. Loo, C. Dive, Jimmy Lin, M. Rabinowitz, H. Aerts, A. Hackshaw, J. Shaw, B. Zimmermann, C. Swanton (2017)
Phylogenetic ctDNA analysis depicts early stage lung cancer evolutionNature, 545
N. Guibert, M. Delaunay, A. Lusque, N. Boubekeur, I. Rouquette, E. Clermont, J. Mourlanette, Sandrine Gouin, Inge Dormoy, G. Favre, J. Mazières, A. Pradines (2018)
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.Lung cancer, 120
Junyun Wang, Shuang Chang, Guochao Li, Yingli Sun (2017)
Application of liquid biopsy in precision medicine: opportunities and challengesFrontiers of Medicine, 11
S. Basnet, Zhen-yu Zhang, W. Liao, Shu-heng Li, Ping Li, H. Ge (2016)
The Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-AnalysisJournal of Cancer, 7
J. Higginson (1968)
International Agency for Research on Cancer.WHO chronicle, 22 12
M. Gerlinger, A. Rowan, S. Horswell, M. Math, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, P. Tarpey, I. Varela, B. Phillimore, Sharmin Begum, N. McDonald, A. Butler, David Jones, K. Raine, Calli Latimer, Claudio Santos, M. Nohadani, A. Eklund, B. Spencer‐Dene, G. Clark, L. Pickering, G. Stamp, M. Gore, Z. Szallasi, J. Downward, P. Futreal, C. Swanton (2012)
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.The New England journal of medicine, 366 10
C. Abbosh, N. Birkbak, C. Swanton (2018)
Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detectionNature Reviews Clinical Oncology, 15
S. Rasmussen, H. Krarup, K. Sunesen, M. Johansen, M. Stender, I. Pedersen, P. Madsen, O. Thorlacius-Ussing (2017)
Hypermethylated DNA, a circulating biomarker for colorectal cancer detectionPLoS ONE, 12
J. Moscow, T. Fojo, R. Schilsky (2018)
The evidence framework for precision cancer medicineNature Reviews Clinical Oncology, 15
A. Andermann, I. Blancquaert, S. Beauchamp, V. Déry (2008)
Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years.Bulletin of the World Health Organization, 86 4
L. Stone (2016)
Prostate cancer: Biomarkers from liquid biopsyNature Reviews Urology, 13
E. Heitzer, Martina Auer, Christin Gasch, M. Pichler, Peter Ulz, E. Hoffmann, S. Lax, Julie Waldispuehl-Geigl, Oliver Mauermann, C. Lackner, G. Höfler, F. Eisner, H. Sill, H. Samonigg, K. Pantel, S. Riethdorf, T. Bauernhofer, J. Geigl, M. Speicher (2013)
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing.Cancer research, 73 10
(2020)
General ConceptsOptimization for Chemical and Biochemical Engineering
Lydia Giannopoulou, S. Kasimir-Bauer, E. Lianidou (2017)
Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNAClinical Chemistry and Laboratory Medicine (CCLM), 56
Aaron Newman, A. Lovejoy, D. Klass, D. Kurtz, J. Chabon, F. Scherer, H. Stehr, C. Liu, S. Bratman, C. Say, Li Zhou, Justin Carter, R. West, G. Sledge, J. Shrager, B. Loo, J. Neal, H. Wakelee, M. Diehn, Ash Alizadeh (2016)
Integrated digital error suppression for improved detection of circulating tumor DNANature biotechnology, 34
Scott Kennedy, Michael Schmitt, E. Fox, Brendan Kohrn, J. Salk, E. Ahn, Marc Prindle, Kawai Kuong, Jiang-Cheng Shen, R. Risques, L. Loeb (2014)
Detecting ultralow-frequency mutations by Duplex SequencingNature Protocols, 9
Zhong-Hua Lin, Yong-Ning Xin, Q. Dong, Qing Wang, Xiang-Jun Jiang, Shu-Hui Zhan, Ying Sun, S. Xuan (2010)
Association between HLA-DRB1 alleles polymorphism and hepatocellular carcinoma: a meta-analysisBMC Gastroenterology, 10
N. Silvestris, G. Ciliberto, P. Paoli, G. Apolone, M. Lavitrano, M. Pierotti, G. Stanta (2017)
Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology researchJournal of Experimental & Clinical Cancer Research : CR, 36
Youwei Zhang, Rui Wang, Haizhu Song, Guichun Huang, J. Yi, Yun Zheng, Jing-hua Wang, Long-Bang Chen (2011)
Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer.Cancer letters, 303 1
M. Sausen, J. Phallen, V. Adleff, Siân Jones, R. Leary, M. Barrett, V. Anagnostou, S. Parpart-Li, D. Murphy, Qing Li, C. Hruban, R. Scharpf, J. White, P. O'dwyer, P. Allen, J. Eshleman, C. Thompson, D. Klimstra, D. Linehan, A. Maitra, R. Hruban, Luis Diaz, D. Hoff, J. Johansen, J. Drebin, V. Velculescu (2015)
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patientsNature Communications, 6
Yuebi Hu, B. Ulrich, Julianna Supplee, Y. Kuang, Patrick Lizotte, N. Feeney, N. Guibert, M. Awad, Kwok-kin Wong, P. Jänne, C. Paweletz, G. Oxnard (2018)
False-Positive Plasma Genotyping Due to Clonal HematopoiesisClinical Cancer Research, 24
(2014)
Detection of circulating tumor DNA in early- and late-stage human malignanciesSci Transl Med, 6
M. Cristofanilli, S. Braun (2010)
Circulating tumor cells revisited.JAMA, 303 11
Thijssen Ma, Swinkels Dw, Ruers Tj, D. Jb (2002)
Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases.Anticancer Research, 22
Mhairi Harper, Kristy McKeating, K. Faulds (2013)
Recent developments and future directions in SERS for bioanalysis.Physical chemistry chemical physics : PCCP, 15 15
Quan Zhou, Wei Li, Bingjie Leng, Wen-Chen Zheng, Ze He, Manzhen Zuo, Aihua Chen (2016)
Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-AnalysisPLoS ONE, 11
Xiaolin Wu, Jiahui Li, A. Gassa, D. Buchner, H. Alakus, Q. Dong, N. Ren, Ming Liu, M. Odenthal, D. Stippel, C. Bruns, Yue Zhao, R. Wahba (2020)
Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinomaInternational Journal of Biological Sciences, 16
N. Muhanna, Marco Grappa, H. Chan, Tahsin Khan, C. Jin, Yangqiao Zheng, J. Irish, S. Bratman (2017)
Cell-Free DNA Kinetics in a Pre-Clinical Model of Head and Neck CancerScientific Reports, 7
G. Oxnard, T. Maddala, E. Hubbell, A. Aravanis, N. Zhang, Oliver Venn, Anton Valouev, Ling Shen, Shilpen Patel, A. Jamshidi, K. Jagadeesh, S. Gross, D. Filippova, J. Beausang, Minetta Liu, D. Richards, S. Plevritis, R. Williams, A. Hartman, C. Swanton (2018)
Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study.Journal of Clinical Oncology
F. Calabrese, F. Lunardi, F. Pezzuto, F. Fortarezza, S. Vuljan, C. Marquette, P. Hofman (2019)
Are There New Biomarkers in Tissue and Liquid Biopsies for the Early Detection of Non-Small Cell Lung Cancer?Journal of Clinical Medicine, 8
(2017)
Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicineAnn Oncol, 28
A. Riediger, S. Dietz, Uwe Schirmer, M. Meister, I. Heinzmann-Groth, M. Schneider, T. Muley, Michael Thomas, H. Sültmann (2016)
Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patientsScientific Reports, 6
P. Bonazzi, C. Calaresu, R. Galeazzi (1984)
Bile acid analysis: a rapid and sensitive gas-liquid chromatographic method.Pharmacological research communications, 16 6
(Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open. 2013;3(1):e001570. 10.1136/bmjopen-2012-001570.)
Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open. 2013;3(1):e001570. 10.1136/bmjopen-2012-001570.Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open. 2013;3(1):e001570. 10.1136/bmjopen-2012-001570., Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open. 2013;3(1):e001570. 10.1136/bmjopen-2012-001570.
A. Thierry (2018)
A Step Closer to Cancer Screening by Blood Test.Clinical chemistry, 64 10
Y. Chae, A. Davis, Sarika Jain, C. Santa-Maria, Lisa Flaum, N. Beaubier, L. Platanias, W. Gradishar, F. Giles, M. Cristofanilli (2017)
Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast CancerMolecular Cancer Therapeutics, 16
G. Poulet, J. Massias, V. Taly (2019)
Liquid Biopsy: General ConceptsActa Cytologica, 63
Roshni Mathai, R. Vidya, B. Reddy, L. Thomas, K. Udupa, J. Kolesar, Mahadev Rao (2019)
Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision OncologyJournal of Clinical Medicine, 8
P. Cohen, N. Flowers, S. Tong, N. Hannan, M. Pertile, L. Hui (2016)
Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screeningBMC Medicine, 14
T. Forshew, M. Murtaza, C. Parkinson, D. Gale, D. Tsui, F. Kaper, S. Dawson, A. Piskorz, M. Jimenez-Linan, D. Bentley, J. Hadfield, A. May, C. Caldas, J. Brenton, N. Rosenfeld (2012)
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNAScience Translational Medicine, 4
Jonathan Wan, C. Massie, J. García-Corbacho, F. Mouliere, J. Brenton, C. Caldas, S. Pacey, R. Baird, N. Rosenfeld (2017)
Liquid biopsies come of age: towards implementation of circulating tumour DNANature Reviews Cancer, 17
D. Dressman, Hainen Yan, G. Traverso, K. Kinzler, B. Vogelstein (2003)
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variationsProceedings of the National Academy of Sciences of the United States of America, 100
Michael Mosko, A. Nakorchevsky, E. Flores, H. Metzler, M. Ehrich, D. Boom, James Sherwood, A. Nygren (2016)
Ultrasensitive Detection of Multiplexed Somatic Mutations Using MALDI-TOF Mass Spectrometry.The Journal of molecular diagnostics : JMD, 18 1
E. Vietsch, G. Graham, Justine McCutcheon, A. Javaid, G. Giaccone, J. Marshall, A. Wellstein (2017)
Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer.Cancer genetics, 218-219
J. Rahier, A. Druez, Laurence Faugeras, J. Martinet, M. Géhénot, Eléonore Josseaux, M. Herzog, J. Micallef, Fabienne George, M. Delos, T. Ronde, A. Badaoui, L. D'Hondt (2017)
Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancerClinical Epigenetics, 9
Yvette Lamb, Sohita Dhillon (2017)
Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal CancerMolecular Diagnosis & Therapy, 21
L. Sholl, D. Aisner, M. Varella-Garcia, L. Berry, D. Dias-Santagata, I. Wistuba, Heidi Chen, J. Fujimoto, K. Kugler, Wilbur Franklin, A. Iafrate, M. Ladanyi, M. Kris, Bruce Johnson, P. Bunn, John Minna, David Kwiatkowski (2015)
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium ExperienceJournal of Thoracic Oncology, 10
N. Ramalingam, S. Jeffrey (2018)
Future of Liquid Biopsies With Growing Technological and Bioinformatics Studies: Opportunities and Challenges in Discovering Tumor Heterogeneity With Single-Cell Level AnalysisThe Cancer Journal, 24
L. Diaz, A. Bardelli (2014)
Liquid biopsies: genotyping circulating tumor DNA.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 6
S. Couraud, Felipe Vaca-Paniagua, S. Villar, J. Oliver, T. Schuster, H. Blanché, N. Girard, J. Trédaniel, L. Guilleminault, R. Gervais, N. Prim, M. Vincent, J. Margery, S. Larivé, P. Foucher, B. Duvert, M. Vallée, F. Calvez-Kelm, J. Mckay, P. Missy, F. Morin, G. Zalcman, M. Olivier, P. Souquet (2014)
Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002Clinical Cancer Research, 20
W. Kohlsdorfer, P. Rösen, H. Reinauer (1980)
Metabolic Performance and Insulin Binding of Mammary Cells Isolated from Wistar and Zucker RatsHorm. Metab. Res., 12
C. Kahlert (2019)
Liquid Biopsy: Is There an Advantage to Analyzing Circulating Exosomal DNA Compared to cfDNA or Are They the Same?Cancer research, 79 10
S. McGuire (2016)
World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015.Advances in nutrition, 7 2
M. Uríbarri, I. Hormaeche, R. Zalacaín, G. López-Vivanco, A. Martínez, D. Nagore, M. Ruiz-Argüello (2014)
A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer DiagnosisJournal of Thoracic Oncology, 9
J. Beaver, D. Jelovac, S. Balukrishna, R. Cochran, Sarah Croessmann, Daniel Zabransky, Hong Wong, P. Toro, Justin Cidado, B. Blair, David Chu, T. Burns, M. Higgins, V. Stearns, L. Jacobs, M. Habibi, J. Lange, P. Hurley, J. Lauring, Dustin VanDenBerg, J. Kessler, S. Jeter, M. Samuels, Dianna Maar, L. Cope, A. Cimino-Mathews, P. Argani, A. Wolff, B. Park (2014)
Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast CancerClinical Cancer Research, 20
I. Batth, A. Mitra, S. Manier, I. Ghobrial, D. Menter, S. Kopetz, S. Li (2019)
Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.Annals of oncology : official journal of the European Society for Medical Oncology
M. Delgado-Ureña, F. Ortega, Diego Miguel-Pérez, Alba Rodríguez-Martínez, J. García-Puche, Hugh Ilyine, J. Lorente, J. Expósito-Hernández, M. Garrido-Navas, Miguel Delgado-Ramirez, M. Serrano (2018)
Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patientsJournal of Translational Medicine, 16
R. Aarthy, Samson Mani, S. Velusami, S. Sundarsingh, T. Rajkumar (2015)
Role of Circulating Cell-Free DNA in CancersMolecular Diagnosis & Therapy, 19
(Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425120/. Accessed 30 Sep 2020.)
Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425120/. Accessed 30 Sep 2020.Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425120/. Accessed 30 Sep 2020., Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425120/. Accessed 30 Sep 2020.
(The ASCO Post. FDA approves cobas EGFR mutation test v2 as companion diagnostic with gefitinib in first-line treatment of NSCLC. 2018. https://www.ascopost.com/News/59214. Accessed 1 June 2019.)
The ASCO Post. FDA approves cobas EGFR mutation test v2 as companion diagnostic with gefitinib in first-line treatment of NSCLC. 2018. https://www.ascopost.com/News/59214. Accessed 1 June 2019.The ASCO Post. FDA approves cobas EGFR mutation test v2 as companion diagnostic with gefitinib in first-line treatment of NSCLC. 2018. https://www.ascopost.com/News/59214. Accessed 1 June 2019., The ASCO Post. FDA approves cobas EGFR mutation test v2 as companion diagnostic with gefitinib in first-line treatment of NSCLC. 2018. https://www.ascopost.com/News/59214. Accessed 1 June 2019.
J. Joseph (2010)
Genetic Research in Psychiatry and Psychology
Brayan Seixas (2017)
Welfarism and extra-welfarism: a critical overview.Cadernos de saude publica, 33 8
J. Beane, Joshua Campbell, J. Lel, Jessica Vick, A. Spira (2017)
Genomic approaches to accelerate cancer interception.The Lancet. Oncology, 18 8
T. Govers, D. Hessels, V. Vlaeminck-Guillem, Bernd Schmitz-Dräger, Christian Stief, C. Martínez-Ballesteros, M. Ferro, Á. Borque‐Fernando, J. Rubio-Briones, J. Sedelaar, W. Criekinge, J. Schalken (2018)
Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling studyProstate Cancer and Prostatic Diseases, 22
Mariantonia Sanzo, L. Cipolloni, M. Borro, R. Russa, Alessandro Santurro, M. Scopetti, M. Simmaco, P. Frati (2017)
Clinical Applications of Personalized Medicine: A New Paradigm and Challenge.Current pharmaceutical biotechnology, 18 3
C. Doyle, L. Lennox, D. Bell (2013)
A systematic review of evidence on the links between patient experience and clinical safety and effectivenessBMJ Open, 3
G. Ponti, M. Manfredini, A. Tomasi (2019)
Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology.Critical reviews in oncology/hematology, 141
L. Sorber, K. Zwaenepoel, K. Winne, K. Casteren, Elien Augustus, J. Jacobs, Xianghua Zhang, D. Galdermans, E. Droogh, Anneke Lefebure, Ann-Marie Morel, E. Saenen, F. Bustin, I. Demedts, U. Himpe, T. Pieters, P. Germonpre, S. Derijcke, K. Deschepper, J. Meerbeeck, C. Rolfo, P. Pauwels (2018)
A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical SettingCancers, 10
C. Rolfo, P. Mack, G. Scagliotti, P. Baas, F. Barlesi, T. Bivona, R. Herbst, T. Mok, N. Peled, R. Pirker, L. Raez, M. Reck, J. Riess, L. Sequist, F. Shepherd, L. Sholl, D. Tan, H. Wakelee, I. Wistuba, M. Wynes, D. Carbone, F. Hirsch, D. Gandara (2018)
Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLCJournal of Thoracic Oncology, 13
A. Zehir, R. Benayed, Ronak Shah, Aijazuddin Syed, S. Middha, H. Kim, P. Srinivasan, Jianjiong Gao, D. Chakravarty, S. Devlin, M. Hellmann, D. Barron, A. Schram, M. Hameed, S. Dogan, D. Ross, J. Hechtman, D. DeLair, Jinjuan Yao, D. Mandelker, Donavan Cheng, Raghu Chandramohan, A. Mohanty, R. Ptashkin, G. Jayakumaran, Meera Prasad, M. Syed, A. Rema, Zhen Liu, K. Nafa, L. Borsu, Justyna Sadowska, J. Casanova, R. Bacares, I. Kiecka, A. Razumova, J. Son., L. Stewart, Tessara Baldi, Kerry Mullaney, H. Al-Ahmadie, E. Vakiani, Adam Abeshouse, A. Penson, P. Jonsson, Niedzica Camacho, Matthew Chang, H. Won, Benjamin Gross, Ritika Kundra, Zachary Heins, Hsiao-Wei Chen, Sarah Phillips, Hongxin Zhang, Jiaojiao Wang, Angelica Ochoa, J. Wills, Michael Eubank, S. Thomas, Stuart Gardos, D. Reales, J. Galle, R. Durany, R. Cambria, W. Abida, A. Cercek, D. Feldman, M. Gounder, A. Hakimi, J. Harding, G. Iyer, Y. Janjigian, E. Jordan, C. Kelly, M. Lowery, L. Morris, A. Omuro, N. Raj, P. Razavi, A. Shoushtari, N. Shukla, Tara Soumerai, A. Varghese, R. Yaeger, J. Coleman, B. Bochner, Gregory Riely, L. Saltz, H. Scher, P. Sabbatini, M. Robson, D. Klimstra, B. Taylor, J. Baselga, N. Schultz, D. Hyman, M. Arcila, D. Solit, M. Ladanyi, M. Berger (2017)
Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 PatientsNature medicine, 23
L. Sorber, K. Zwaenepoel, V. Deschoolmeester, G. Roeyen, F. Lardon, C. Rolfo, P. Pauwels (2017)
A Comparison of Cell-Free DNA Isolation Kits: Isolation and Quantification of Cell-Free DNA in Plasma.The Journal of molecular diagnostics : JMD, 19 1
J. Phallen, M. Sausen, V. Adleff, A. Leal, C. Hruban, J. White, V. Anagnostou, J. Fiksel, S. Cristiano, E. Papp, S. Speir, T. Reinert, Mai-Britt Orntoft, B. Woodward, D. Murphy, S. Parpart-Li, David Riley, Monica Nesselbush, Naomi Sengamalay, Andrew Georgiadis, Q. Li, M. Madsen, F. Mortensen, J. Huiskens, C. Punt, N. Grieken, R. Fijneman, G. Meijer, H. Husain, R. Scharpf, L. Diaz, Siân Jones, Samuel Angiuoli, T. Ørntoft, H. Nielsen, C. Andersen, V. Velculescu (2017)
Direct detection of early-stage cancers using circulating tumor DNAScience Translational Medicine, 9
P. Jänne, G. Oxnard, K. Thress, R. Alden, R. Lawrance (2016)
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 28
P. Romero-Palacios, B. Alcázar-Navarrete, J. Mochon, Diego Miguel-Pérez, J. Hidalgo, M. Garrido-Navas, Florencio Valenzuela, J. Lorente, M. Serrano (2019)
Liquid biopsy beyond of cancer: Circulating pulmonary cells as biomarkers of COPD aggressivity.Critical reviews in oncology/hematology, 136
Wataru Okajima, S. Komatsu, D. Ichikawa, Mahito Miyamae, Takuma Ohashi, Taisuke Imamura, Jun Kiuchi, Keiji Nishibeppu, T. Arita, H. Konishi, A. Shiozaki, R. Morimura, H. Ikoma, K. Okamoto, E. Otsuji (2017)
Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acidsWorld Journal of Gastroenterology, 23
V. Cappelletti, V. Appierto, P. Tiberio, E. Fina, M. Callari, M. Daidone (2015)
Circulating Biomarkers for Prediction of Treatment Response.Journal of the National Cancer Institute. Monographs, 2015 51
A. Otandault, P. Anker, Z. Dache, V. Guillaumon, R. Meddeb, B. Pastor, E. Pisareva, Cynthia Sanchez, R. Tanos, G. Tousch, H. Schwarzenbach, Alain Thierry (2019)
Recent advances in circulating nucleic acids in oncology.Annals of oncology : official journal of the European Society for Medical Oncology, 30 3
B. Shapiro, Milankumar Chakrabarty, E. Cohn, S. Leon (1983)
Determination of circulating DNA levels in patients with benign or malignant gastrointestinal diseaseCancer, 51
A. Thierry, S. Messaoudi, P. Gahan, Philippe Anker, M. Stroun (2016)
Origins, structures, and functions of circulating DNA in oncologyCancer Metastasis Reviews, 35
C. Paweletz, A. Sacher, C. Raymond, R. Alden, Allison O'Connell, Stacy Mach, Y. Kuang, L. Gandhi, P. Kirschmeier, J. English, L. Lim, P. Jänne, G. Oxnard (2015)
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer PatientsClinical Cancer Research, 22
C. Hiley, E. Bruin, N. Mcgranahan, C. Swanton (2014)
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicineGenome Biology, 15
L. Kristensen, L. Hansen (2009)
PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment.Clinical chemistry, 55 8
D. Steensma, R. Bejar, S. Jaiswal, R. Lindsley, M. Sekeres, R. Hasserjian, B. Ebert (2015)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.Blood, 126 1
Definition: liquid biopsy
L. Stone (2016)
Prostate cancer: Midlife PSA levels predict lethal diseaseNature Reviews Urology, 13
M. Shan, Huizi Yin, Junnan Li, Xiaobo Li, Dong Wang, Yonghui Su, M. Niu, Zhenbin Zhong, Ji Wang, Xianyu Zhang, Wenli Kang, D. Pang (2016)
Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancerOncotarget, 7
K. Nandi, R. Verma, R. Dawar, B. Goswami (2020)
Cell free DNA: revolution in molecular diagnostics – the journey so farHormone Molecular Biology and Clinical Investigation, 41
F. Diehl, Kerstin Schmidt, M. Choti, K. Romans, S. Goodman, M. Li, K. Thornton, N. Agrawal, L. Sokoll, Steve Szabo, K. Kinzler, B. Vogelstein, L. Diaz (2008)
Circulating mutant DNA to assess tumor dynamicsNature Medicine, 14
C. Gibson, D. Steensma (2018)
New Insights from Studies of Clonal HematopoiesisClinical Cancer Research, 24
(Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403):eaan2415. 10.1126/scitranslmed.aan2415.)
Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403):eaan2415. 10.1126/scitranslmed.aan2415.Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403):eaan2415. 10.1126/scitranslmed.aan2415., Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403):eaan2415. 10.1126/scitranslmed.aan2415.
B. Molnár, K. Tóth, B. Barták, Z. Tulassay (2015)
Plasma methylated septin 9: a colorectal cancer screening markerExpert Review of Molecular Diagnostics, 15
(Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86(4):317–9. 10.2471/blt.07.050112.)
Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86(4):317–9. 10.2471/blt.07.050112.Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86(4):317–9. 10.2471/blt.07.050112., Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86(4):317–9. 10.2471/blt.07.050112.
Azeet Narayan, N. Carriero, S. Gettinger, Jeannie Kluytenaar, K. Kozak, T. Yock, N. Muscato, P. Ugarelli, R. Decker, Abhijit Patel (2012)
Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing.Cancer research, 72 14
A. Bronkhorst, Vida Ungerer, S. Holdenrieder (2019)
The emerging role of cell-free DNA as a molecular marker for cancer managementBiomolecular Detection and Quantification, 17
Dipesh Yadav, X. Bai, R. Yadav, Alina Singh, Guogang Li, T. Ma, Wei Chen, T. Liang (2018)
Liquid biopsy in pancreatic cancer: the beginning of a new eraOncotarget, 9
Ming Yi, D. Jiao, Hanxiao Xu, Qian Liu, Weiheng Zhao, Xinwei Han, Kongming Wu (2018)
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitorsMolecular Cancer, 17
T. Takeshita, Yutaka Yamamoto, M. Yamamoto-Ibusuki, M. Tomiguchi, Aiko Sueta, K. Murakami, Y. Omoto, H. Iwase (2017)
Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patientsOncotarget, 8
A. Boire, D. Brandsma, P. Brastianos, É. Rhun, M. Ahluwalia, L. Junck, M. Glantz, M. Groves, E. Lee, N. Lin, J. Raizer, R. Rudà, M. Weller, M. Bent, M. Vogelbaum, Susan Chang, P. Wen, R. Soffietti (2019)
Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applicationsNeuro-Oncology, 21
(National Cancer Institute. Definition: liquid biopsy. https://www.cancer.gov/search/results?swKeyword=liquid+biopsy. Accessed 1 June 2019.)
National Cancer Institute. Definition: liquid biopsy. https://www.cancer.gov/search/results?swKeyword=liquid+biopsy. Accessed 1 June 2019.National Cancer Institute. Definition: liquid biopsy. https://www.cancer.gov/search/results?swKeyword=liquid+biopsy. Accessed 1 June 2019., National Cancer Institute. Definition: liquid biopsy. https://www.cancer.gov/search/results?swKeyword=liquid+biopsy. Accessed 1 June 2019.
U. Malapelle, R. Sirera, E. Jantus-Lewintre, Pablo Reclusa, S. Calabuig-Fariñas, A. Blasco, P. Pisapia, C. Rolfo, C. Camps (2017)
Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancerExpert Review of Molecular Diagnostics, 17
Zibo Li, Xinwu Guo, L. Tang, Limin Peng, Ming Chen, Xipeng Luo, Shouman Wang, Zhi Xiao, Zhongping Deng, L. Dai, K. Xia, Jun Wang (2016)
Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencingTumor Biology, 37
B.T. Li, F. Janku, B. Jung, C. Hou, K. Madwani, R. Alden, P. Razavi, J. Reis-Filho, R. Shen, J. Isbell, A. Blocker, N. Eattock, S. Gnerre, R. Satya, H. Xu, C. Zhao, M. Hall, Y. Hu, A. Sehnert, D. Brown, M. Ladanyi, C. Rudin, N. Hunkapiller, N. Feeney, G. Mills, C. Paweletz, P. Janne, D. Solit, Gregory Riely, A. Aravanis, G. Oxnard (2019)
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.Annals of oncology : official journal of the European Society for Medical Oncology, 30 4
L. Shlush (2018)
Age-related clonal hematopoiesis.Blood, 131 5
S. Jia, Rui Zhang, Ziyang Li, Jinming Li (2017)
Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancerOncotarget, 8
B. Silva, A. Leitato (1984)
UV‐INDUCTION OF SOS RESPONSES IN Staphylococcus epidermidis: CHARACTERISTICS OF THE PROCESSPhotochemistry and Photobiology, 39
B. Vogelstein, K. Kinzler (1999)
Digital PCR.Proceedings of the National Academy of Sciences of the United States of America, 96 16
A. Bagheri, H. Khorshid, M. Tavallaie, S. Mowla, M. Sherafatian, M. Rashidi, M. Zargari, M. Boroujeni, S. Hosseini (2018)
A panel of noncoding RNAs in non–small‐cell lung cancerJournal of Cellular Biochemistry, 120
K. Patel, D. Tsui (2015)
The translational potential of circulating tumour DNA in oncology.Clinical biochemistry, 48 15
F. Diehl, M. Li, D. Dressman, Yiping He, D. Shen, Steve Szabo, L. Diaz, S. Goodman, K. David, H. Juhl, K. Kinzler, B. Vogelstein (2005)
Detection and quantification of mutations in the plasma of patients with colorectal tumors.Proceedings of the National Academy of Sciences of the United States of America, 102 45
(2019)
FDA approves cobas EGFR mutation test v2 as companion diagnostic with gefitinib in first-line treatment of NSCLC. 2018
S. Leon, B. Shapiro, D. Sklaroff, M. Yaros (1977)
Free DNA in the serum of cancer patients and the effect of therapy.Cancer research, 37 3
M. Neumann, S. Bender, T. Krahn, T. Schlange (2018)
ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to ProgressComputational and Structural Biotechnology Journal, 16
Glen Francis, S. Stein (2015)
Circulating Cell-Free Tumour DNA in the Management of CancerInternational Journal of Molecular Sciences, 16
Qian Chen, Zifan Zhang, Shu Wang, J. Lang (2019)
Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial CancerOncoTargets and therapy, 12
A. Bronkhorst, Johannes Wentzel, Vida Ungerer, D. Peters, J. Aucamp, E. Villiers, S. Holdenrieder, P. Pretorius (2018)
Sequence analysis of cell-free DNA derived from cultured human bone osteosarcoma (143B) cellsTumor Biology, 40
Precision medicine has impacted the field of medical oncology by introducing personalized therapies, improving all measurable outcomes. This field, in turn, has expanded to obtaining and analyzing a vast and ever-increasing amount of genomic information. One technique currently applied is the liquid biopsy, which consists of detecting and isolating DNA and exosomes in cancer patients. Newly developed techniques have made it possible to use the liquid biopsy in a wide range of settings. However, challenges regarding the validation of its clinical utility exist because of a lack of standardization across different techniques and tumor types, confounder genomic information, lack of appropriate clinical trial designs, and a non-measured, and therefore not estimated, economic impact on population health. Nowadays, liquid biopsy is not routinely used, but ongoing research is increasing its popularity, and a new era in oncology is developing. Therefore, it is essential to have an in-depth understanding of the liquid biopsy technique. In this review, we summarize the leading techniques and liquid biopsy applications in cancer.
Oncology and Therapy – Springer Journals
Published: Mar 10, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.